Vaccine plus drug combination for advanced fibrolamellar carcinoma
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new vaccine (a shot that may help your immune system attack cancer cells) combined with a glutamine-blocking drug (DRP-104) and two immunotherapy drugs (nivolumab and ipilimumab) for advanced fibrolamellar carcinoma. It aims to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have fibrolamellar carcinoma, a rare type of liver cancer, that has spread or cannot be removed by surgery.
- Your tumor must have a specific genetic change called the DNAJB1-PRKACA fusion, which is found through a tissue test.
- You must have already tried immunotherapy, and your cancer must have continued to grow during that treatment.
- You need to be at least 12 years old and weigh at least 40 kg (about 88 pounds).
- You must have normal kidney and liver function, and be able to provide blood and tissue samples for research.
- You cannot have an active autoimmune disease, active infections (like HIV or hepatitis B), or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
This trial tests a patient-specific vaccine for people who have a rare type of liver cancer called fibrolamellar hepatocellular carcinoma (FL-HCC), or another cancer with the same genetic change. The vaccine is given after the cancer has been completely removed or treated, and it aims to teach your immune system to recognize and destroy any cancer cells that might be left.
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
This Phase 1/2 trial tests whether nivolumab combined with fluorouracil and interferon alpha can treat fibrolamellar liver cancer that cannot be safely removed with surgery. It aims to shrink or control the cancer and to see how safe the combination is.
This trial tests a new drug combination for liver cancer that has progressed after standard treatment. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Hear when a new Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.